公开(公告)号：US20240342203A1

公开(公告)日：2024-10-17

申请号：US18750831

申请日：2024-06-21

申请人： GR BIOSYSTEMS, INC.

发明人： Andrew J. GROSS ,  Shane RIRIE

IPC分类号： A61K31/7034 ,  A61K9/00 ,  A61K31/12 ,  A61K31/121 ,  A61K31/16 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/7056 ,  A61K47/34 ,  A61P35/00

CPC分类号： A61K31/7034 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/0063 ,  A61K31/12 ,  A61K31/121 ,  A61K31/16 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/7056 ,  A61K47/34 ,  A61P35/00

摘要： The present disclosure generally relates to compositions that inhibit matrix metalloproteinases (MMPs). These compositions may be particularly useful in treating oral cancer or an oropharyngeal cancer. The compositions can be prepared as a topical formulation, ointment, mouthwash, or packaged in a syringe.

公开(公告)号：US12115138B2

公开(公告)日：2024-10-15

申请号：US16811759

申请日：2020-03-06

申请人： RENIBUS THERAPEUTICS, INC.

发明人： Donald Jeffrey Keyser ,  Alvaro F. Guillem ,  Bhupinder Singh ,  Richard A. Zager

IPC分类号： A61K31/12 ,  A61K9/127 ,  A61K31/145 ,  A61K31/16 ,  A61K31/355 ,  A61K31/375 ,  A61K31/385 ,  A61K31/7048 ,  A61K47/10 ,  A61K47/24 ,  A61K47/34

CPC分类号： A61K31/12 ,  A61K9/127 ,  A61K31/145 ,  A61K31/16 ,  A61K31/355 ,  A61K31/375 ,  A61K31/385 ,  A61K31/7048 ,  A61K47/10 ,  A61K47/24 ,  A61K47/34

摘要： The present invention relates to novel tetrahydrocurcumin (THCu) compositions, novel methods of manufacturing, and methods of using these compositions for therapeutic applications. The novel synthetic pathway(s) result in THCu compositions that generally lack hexahydrocurcumin (HHC), and include an improved impurity profile with reduced additional species that are generally present in hydrogenated curcumin compositions.

公开(公告)号：US12109263B2

公开(公告)日：2024-10-08

申请号：US17471922

申请日：2021-09-10

申请人： 7 Hills Pharma LLC

发明人： Robert W Strozier

IPC分类号： A61K39/39 ,  A61K31/16 ,  A61K31/381 ,  A61K31/404 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/4439 ,  A61K39/00 ,  A61K47/60 ,  A61P37/04

CPC分类号： A61K39/39 ,  A61K31/16 ,  A61K31/381 ,  A61K31/404 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/4439 ,  A61K39/0011 ,  A61K47/60 ,  A61P37/04 ,  A61K2039/55511

摘要： Small molecule integrin agonists or integrin activating compounds including at least one di-alkylaryl amine end group and at least one alkyl or alkenoxy linking group including at least one protonatable moiety, wherein the compounds enhance vaccine efficacies, enhance adoptive cell therapy efficacies, enhance immunotherapy efficacies, enhance therapeutic antibody therapy efficacies, enhance checkpoint inhibitor therapy efficacies, enhance effector cell therapy efficacies, and enhanced cell based transplant efficacies and wherein at protonatable moiety either protonate at biological pHs or bears a charge with associated pharmaceutically acceptable counterion making the compound water soluble to improve bioavailability and methods for making and using same.

公开(公告)号：US20240307332A1

公开(公告)日：2024-09-19

申请号：US18528397

申请日：2023-12-04

申请人： CASE WESTERN RESERVE UNIVERSITY

发明人： Bin SU ,  Monica M. MONTANO

IPC分类号： A61K31/18 ,  A61K31/16 ,  A61K45/06

CPC分类号： A61K31/18 ,  A61K31/16 ,  A61K45/06

摘要： A method of inducing HEXIM1 expression in cells of a subject includes administering to the cells a compound having the formula,




and pharmaceutically acceptable salts thereof.

公开(公告)号：US20240277649A1

公开(公告)日：2024-08-22

申请号：US18623536

申请日：2024-04-01

申请人： Epitracker, Inc.

发明人： Stephanie Venn-Watson ,  John Reiner ,  Richard Lumpkin

IPC分类号： A61K31/20 ,  A61K31/16 ,  A61K31/41 ,  A61K31/421 ,  A61K31/4245

CPC分类号： A61K31/20 ,  A61K31/16 ,  A61K31/41 ,  A61K31/421 ,  A61K31/4245

摘要： Compositions comprising fatty acid analogs are provided for treating metabolic syndrome, anemia, cancer, cardiovascular disease, diabetes, dyslipidemia, hypertension, inflammation, insulin resistance, prediabetes, fatty liver disease, steatohepatitis, iron overload, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions. Methods for the diagnosis and monitoring of metabolic syndrome and other conditions are also provided.

公开(公告)号：US20240254075A1

公开(公告)日：2024-08-01

申请号：US18558726

申请日：2022-05-06

申请人： Autobahn Therapeutics, Inc.

发明人： Brian Andrew STEARNS ,  Jill Melissa BACCEI ,  Jason Randall HARRIS

IPC分类号： C07C235/20 ,  A61K31/16 ,  A61K31/165 ,  A61K31/397 ,  A61K31/40 ,  A61K31/42 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/455 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5375 ,  A61P25/00 ,  C07C235/16 ,  C07C235/22 ,  C07C235/24 ,  C07C243/28 ,  C07C255/29 ,  C07C259/06 ,  C07C313/02 ,  C07C317/28 ,  C07D205/04 ,  C07D213/75 ,  C07D237/20 ,  C07D237/22 ,  C07D239/42 ,  C07D241/20 ,  C07D261/14 ,  C07D295/18 ,  C07D305/08

CPC分类号： C07C235/20 ,  A61K31/16 ,  A61K31/165 ,  A61K31/397 ,  A61K31/40 ,  A61K31/42 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/455 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5375 ,  A61P25/00 ,  C07C235/16 ,  C07C235/22 ,  C07C235/24 ,  C07C243/28 ,  C07C255/29 ,  C07C259/06 ,  C07C313/02 ,  C07C317/28 ,  C07D205/04 ,  C07D213/75 ,  C07D237/20 ,  C07D237/22 ,  C07D239/42 ,  C07D241/20 ,  C07D261/14 ,  C07D295/18 ,  C07D305/08 ,  C07C2601/02 ,  C07C2601/14

摘要： Provided herein are fatty acid amide (FAAH) cleavable prodrugs of thyromimetics and pharmaceutical compositions comprising these compounds with at least one pharmaceutically acceptable excipient further comprising a peripherally restricted FAAH inhibitor.

公开(公告)号：US12037306B2

公开(公告)日：2024-07-16

申请号：US17821035

申请日：2022-08-19

申请人： Warner-Lambert Company LLC

发明人： Erwin Irdam

IPC分类号： A61K31/16 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  A61P35/00 ,  C07C237/28

CPC分类号： C07C237/28 ,  A61K9/0053 ,  A61K9/20 ,  A61K9/48 ,  C07B2200/13

摘要： The present disclosure relates to: a) a crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising the crystalline composition of essentially pure Form IV of N—((R)-2,3-dihvdroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier; and c) methods of treating a tumor, a cancer, or a Rasopathy disorder by administering the crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof.

公开(公告)号：US12016871B2

公开(公告)日：2024-06-25

申请号：US17249976

申请日：2021-03-19

申请人： GR BIOSYSTEMS, INC.

发明人： Andrew J. Gross ,  Shane Ririe

IPC分类号： A61K31/7034 ,  A61K9/00 ,  A61K31/12 ,  A61K31/121 ,  A61K31/16 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/7056 ,  A61K47/34 ,  A61P35/00

CPC分类号： A61K31/7034 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/0063 ,  A61K31/12 ,  A61K31/121 ,  A61K31/16 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/7056 ,  A61K47/34 ,  A61P35/00

摘要： The present disclosure generally relates to compositions that inhibit matrix metalloproteinases (MMPs). These compositions may be particularly useful in treating oral cancer or an oropharyngeal cancer. The compositions can be prepared as a topical formulation, ointment, mouthwash, or packaged in a syringe.

公开(公告)号：US20240199535A1

公开(公告)日：2024-06-20

申请号：US18554365

申请日：2022-04-08

申请人： IMMUNIC AG

发明人： Christian GEGE ,  Hella KOHLHOF ,  Andreas MÜHLER ,  Daniel VITT

IPC分类号： C07C233/75 ,  A61K31/16 ,  A61K31/167 ,  A61K31/341 ,  A61K31/381 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/472 ,  A61K31/5375 ,  A61P31/14 ,  C07C233/74 ,  C07D213/68 ,  C07D213/73 ,  C07D217/04 ,  C07D265/30 ,  C07D277/34 ,  C07D307/30 ,  C07D333/40 ,  C07D471/04

CPC分类号： C07C233/75 ,  A61K31/16 ,  A61K31/167 ,  A61K31/341 ,  A61K31/381 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/472 ,  A61K31/5375 ,  A61P31/14 ,  C07C233/74 ,  C07D213/68 ,  C07D213/73 ,  C07D217/04 ,  C07D265/30 ,  C07D277/34 ,  C07D307/30 ,  C07D333/40 ,  C07D471/04

摘要： The invention relates to novel deuterated compounds of Formula (I)




and their use as medicaments.

公开(公告)号：US20240173240A1

公开(公告)日：2024-05-30

申请号：US18130595

申请日：2023-04-04

申请人： Solus Biotech Co., Ltd.

发明人： So Jung LIM ,  Mi Kyung SUNG ,  Sang Chul KIM ,  Ji Hye HAN ,  Seung Won PARK

IPC分类号： A61K8/68 ,  A61K31/16 ,  A61P17/00 ,  A61Q19/08

CPC分类号： A61K8/68 ,  A61K31/16 ,  A61P17/00 ,  A61Q19/08 ,  A61K2800/78

摘要： Provided is a cosmetic composition including ceramides and a sphingolipid. A composition including two or more different ceramides and a sphingolipid, according to an embodiment, has the activity of increasing a ceramide content in the skin, increasing the expression level of aquaporin 3, increasing the expression level of fillaggrin, increasing the expression level of loricrin, increasing the expression level of involucrin, and increasing the skin thickness, and thus can be effectively used for improving skin conditions.